erlotinib hydrochloride has been researched along with efavirenz in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (efavirenz) | Trials (efavirenz) | Recent Studies (post-2010) (efavirenz) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 3,110 | 631 | 1,611 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | efavirenz (IC50) |
|---|---|---|---|
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
| Chain A, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Chain B, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
| Prothrombin | Bos taurus (cattle) | 0.022 | |
| Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.1852 | |
| Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.02 | |
| Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
| Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.054 | |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.004 | |
| Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Human immunodeficiency virus 1 | 0.0035 | |
| Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.1627 | |
| Reverse transcriptase | Human immunodeficiency virus 1 | 0.0643 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Anders, NM; Beumer, JH; Deeken, JF; Rudek, MA; Rusnak, M; Wanjiku, T | 1 |
2 other study(ies) available for erlotinib hydrochloride and efavirenz
| Article | Year |
|---|---|
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib.
Topics: Administration, Oral; Alkynes; Animals; Anti-Retroviral Agents; Antineoplastic Agents; Benzoxazines; Biological Availability; Biotransformation; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dexamethasone; Drug Evaluation, Preclinical; Drug Interactions; Erlotinib Hydrochloride; Half-Life; Ketoconazole; Male; Metabolic Clearance Rate; Mice, Inbred Strains; Protein Kinase Inhibitors; Quinazolines; Ritonavir | 2015 |